TUS-PHARMACEUTICAL GROUP CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 6.43 CNY | +2.72% |
|
+2.88% | -28.24% |
| Sales 2022 | 351M 48.47M 3.86B | Sales 2023 | 405M 55.96M 4.46B | Capitalization | 2.15B 297M 23.64B |
|---|---|---|---|---|---|
| Net income 2022 | 18M 2.49M 198M | Net income 2023 | 25M 3.46M 275M | EV / Sales 2022 | 5.75 x |
| Net cash position 2022 | 127M 17.53M 1.4B | Net cash position 2023 | 94.34M 13.05M 1.04B | EV / Sales 2023 | 5.07 x |
| P/E ratio 2022 |
118
x | P/E ratio 2023 |
85
x | Employees | 1,237 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 53.4% |
More Fundamentals
* Assessed data
More news
| 1 day | +2.72% | ||
| 1 week | +2.88% | ||
| Current month | -13.81% | ||
| 1 month | -13.46% | ||
| 3 months | -26.51% | ||
| 6 months | -26.35% | ||
| Current year | -28.24% |
1 week
6.06
6.57
1 month
5.808.27
Current year
4.8011.25
1 year
4.8011.25
3 years
4.8013.73
5 years
4.8014.34
10 years
4.8035.83
| Managers | Title | Age | Since |
|---|---|---|---|
Ting Tang
DFI | Director of Finance/CFO | 46 | 11/12/16 |
Xue Feng
PSD | President | 34 | 20/05/20 |
Li Jun Yan
IRC | Investor Relations Contact | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Wei Hua Xie
BRD | Director/Board Member | 53 | 10/06/08 |
Qi Sen Jiao
CHM | Chairman | 43 | 25/10/20 |
Ke Biao Yan
CHM | Chairman | 58 | 07/06/17 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 28/04/24 | 6.43 | +2.72% | 7 634 568 |
| 26/04/24 | 6.26 | -4.57% | 11,450,030 |
| 25/04/24 | 6.56 | +2.34% | 4,745,200 |
| 24/04/24 | 6.41 | +1.75% | 4,502,500 |
| 23/04/24 | 6.3 | +3.79% | 6,881,396 |
End-of-day quote Shenzhen S.E., April 28, 2024
More quotes
Tus Pharmaceutical Group Co Ltd, formerly Tus-Guhan Group Corp Ltd, is principally engaged in the manufacture and sale of pharmaceuticals. The Company provides Chinese medicines, including Chinese healthcare products, medicines for cold treatment and anti hyperlipemia medicines, among others. It also provides western medicine preparations, including clindamycin phosphate for injection, lomefloxacin hydrochloride for injection and levofloxacin lactate for injection, among others. The Company distributes its products in domestic markets.
Sector
Pharmaceuticals
Calendar
28/08/2024
- Q2 2024 Earnings Release (Projected)
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -28.24% | 207M | |
| +26.24% | 661B | |
| +26.74% | 566B | |
| -6.76% | 352B | |
| +19.40% | 332B | |
| +3.56% | 283B | |
| +13.43% | 231B | |
| +4.71% | 200B | |
| -9.53% | 195B | |
| -4.38% | 145B |
- Stock Market
- Equities
- 000590 Stock
